Decibel Therapeutics Inc. (DBTX)
4.91
-0.04 (-0.81%)
At close: Sep 22, 2023, 8:00 PM
-0.81% (1D)
| Bid | n/a |
| Market Cap | 123.37M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -63.39M |
| EPS (ttm) | -2.54 |
| PE Ratio (ttm) | -1.9330708661417324 |
| Forward PE | n/a |
| Analyst | n/a |
| Ask | n/a |
| Volume | 1,055,379 |
| Avg. Volume (20D) | 214,738 |
| Open | 4.92 |
| Previous Close | 4.95 |
| Day's Range | 4.90 - 5.09 |
| 52-Week Range | 1.61 - 5.40 |
| Beta | -0.40 |
About DBTX
Decibel Therapeutics, Inc., a clinical-stage biotechnology company, engages in discovering and developing transformative treatments for hearing and balance disorders. Its product candidates and programs focuses on three areas, such as Gene Therapies for Congenital, Monogenic Hearing Loss designed to restore functional cells within the cochlea to address hearing disorders caused by single gene mutations; Gene Therapies for Hair Cell Regeneration d...
Industry Biotechnology
Sector Healthcare
IPO Date Feb 12, 2021
Employees 68
Stock Exchange NASDAQ
Ticker Symbol DBTX
Website https://www.decibeltx.com